To overcome resistance to targeted therapies in patients with non–small cell lung cancer, a novel approach is given by amivantamab, which belongs to the novel class of EGFR mesenchymal–epithelial transition factor (MET) fully human bispecific antibodies. This evidence concerns the gene EGFR and lung cancer.